Aligos Therapeutics Book Value Per Share Growth & History (ALGS)
Aligos Therapeutics's book value per share was $8.67 for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.67 | $16.16 | — |
| 2024 | 2024-12-31 | -$7.50 | -$38.15 | — |
| 2023 | 2023-12-31 | $30.65 | -$29.86 | −49.35% |
| 2022 | 2022-12-31 | $60.52 | -$47.67 | −44.06% |
| 2021 | 2021-12-31 | $108.18 | -$36.12 | −25.03% |
| 2020 | 2020-12-31 | $144.30 | $557.33 | — |
| 2019 | 2019-12-31 | -$413.02 | — | — |
Aligos Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.11 | -$11.45 | −69.13% |
| Q1 2026 | 2026-03-31 | $5.14 | -$13.91 | −73.02% |
| Q4 2025 | 2025-12-31 | $8.67 | $16.16 | — |
| Q3 2025 | 2025-09-30 | $11.67 | -$3.39 | −22.53% |
| Q2 2025 | 2025-06-30 | $16.56 | -$4.51 | −21.39% |
| Q1 2025 | 2025-03-31 | $19.04 | -$0.71 | −3.61% |
| Q4 2024 | 2024-12-31 | -$7.50 | -$38.15 | — |
| Q3 2024 | 2024-09-30 | $15.07 | -$16.44 | −52.17% |
| Q2 2024 | 2024-06-30 | $21.07 | -$18.95 | −47.36% |
| Q1 2024 | 2024-03-31 | $19.76 | -$29.59 | −59.96% |
| Q4 2023 | 2023-12-31 | $30.65 | -$29.86 | −49.35% |
| Q3 2023 | 2023-09-30 | $31.50 | -$39.74 | −55.78% |
| Q2 2023 | 2023-06-30 | $40.02 | -$39.98 | −49.98% |
| Q1 2023 | 2023-03-31 | $49.34 | -$40.18 | −44.88% |
| Q4 2022 | 2022-12-31 | $60.52 | -$47.67 | −44.06% |
| Q3 2022 | 2022-09-30 | $71.24 | -$56.08 | −44.04% |
| Q2 2022 | 2022-06-30 | $80.00 | -$30.53 | −27.62% |
| Q1 2022 | 2022-03-31 | $89.52 | -$38.42 | −30.03% |
| Q4 2021 | 2021-12-31 | $108.18 | -$36.12 | −25.03% |
| Q3 2021 | 2021-09-30 | $127.32 | $959.73 | — |
| Q2 2021 | 2021-06-30 | $110.52 | — | — |
| Q1 2021 | 2021-03-31 | $127.94 | — | — |
| Q4 2020 | 2020-12-31 | $144.30 | $557.33 | — |
| Q3 2020 | 2020-09-30 | -$832.41 | — | — |
| Q4 2019 | 2019-12-31 | -$413.02 | — | — |
Aligos Therapeutics book value per share trends
Over the last five fiscal years, Aligos Therapeutics's book value per share decreased from $144.30 to $8.67, a change of -$135.64. The latest reported quarter, Q2 2026, shows $5.11.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗